Identification of Prokineticin-2 As Potential Pharmacodynamic Biomarker for Overcoming Doxorubicin Resistance in Multicellular Breast Cancer Spheroids

Scientists explored the effect of a hypoxia-inducible factor inhibitor on viability defect in human 3D breast cancer spheroids and the levels of prokineticin-2 in the conditioned medium following doxorubicin treatment.